Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
Artelo announced the first patient has been dosed in the Phase 2 DREAM study evaluating ART27.13 for the treatment of glaucoma or ocular hypertension. The investigator-led study is fully funded by Glaucoma UK and the HSC R&D Division, sponsored by the Belfast Health and Social Care Trust, and led by Professor Augusto Azuara-Blanco.
Key figures
- Drug Name
- ART27.13
- Phase Of Trial
- Phase 2
- Glaucoma daily dose
- 650 µg
- Cares placebo weight loss
- ~5%
- Cancer anorexia daily dose
- 1300 µg
- Cares weight gain high dose
- +6%
- Previous study participants
- over 280
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.